Contrast-enhanced gray-scale ultrasound for quantitative evaluation of tumor response to chemotherapy: Preliminary results with a mouse hepatoma model

American Journal of Roentgenology

Volumn 196, Issue 1, 2011, Pages

  Zhou, Jian Hua ^a   Cao, Long Hui ^a   Zheng, Wei ^a   Liu, Min ^a   Han, Feng ^a   Li, An Hua ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Chemotherapy; Contrast enhanced ultrasound; Perfusion; Tumor

Indexed keywords

CISPLATIN; PLACEBO; SONOVUE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; GRAY SCALE ECHOGRAPHY; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; NONHUMAN; PERFUSION; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR PERFUSION; TUMOR VOLUME;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CISPLATIN; CONTRAST MEDIA; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS; MICE; PHOSPHOLIPIDS; STATISTICS, NONPARAMETRIC; SULFUR HEXAFLUORIDE;

EID: 78650818244     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.10.4734     Document Type: Article

References (26)

1. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216
2. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J Natl Cancer Inst 2002; 94:883-893 (Pubitemid 34778087)
3. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006; 354:496-507 (Pubitemid 43200300)
4. Ah-See ML, Makris A, Taylor NJ, et al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res 2008; 14:6580-6589
5. Bellomi M, Petralia G, Sonzogni A, Zampino MG, Rocca A. CT perfusion for the monitoring of neoadjuvant chemotherapy and radiation therapy in rectal carcinoma: initial experience. Radiology 2007; 244:486-493 (Pubitemid 47080881)
6. Kumar A, Singh S, Pradhan S, et al. Doppler ultrasound scoring to predict chemotherapeutic response in advanced breast cancer. World J Surg Oncol 2007; 5:99
7. Singh S, Pradhan S, Shukla RC, Ansari MA, Kumar A. Color Doppler ultrasound as an objective assessment tool for chemotherapeutic response in advanced breast cancer. Breast Cancer 2005; 12: 45-51
8. Vallone P, D'Angelo R, Filice S, et al. Color-Doppler using contrast medium in evaluating the response to neoadjuvant treatment in patients with locally advanced breast carcinoma. Anticancer Res 2005; 25:595-599
9. Delorme S, Peschke P, Zuna I, van Kaick G. Imaging the smallest tumor vessels using color Doppler ultrasound in an experiment. Radiologe 2001; 41:168-172
10. McCarville MB, Streck CJ, Dickson PV, Li CS, Nathwani AC, Davidoff AM. Angiogenesis inhibitors in a murine neuroblastoma model: quantitative assessment of intratumoral blood flow with contrast-enhanced gray-scale US. Radiology 2006; 240:73-81
11. Lavisse S, Lejeune P, Rouffiac V, et al. Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062 using dynamic contrastenhanced ultrasonography. Invest Radiol 2008; 43:100-111
12. Broillet A, Hantson J, Ruegg C, Messager T, Schneider M. Assessment of microvascular perfusion changes in a rat breast tumor model using SonoVue to monitor the effects of different anti-angiogenic therapies. Acad Radiol 2005; 12[suppl 1]: S28-S33 (Pubitemid 41150891)
13. Rognin NG, Frinking P, Messager T, Arditi M, Perrenoud G, Meuwly JY. New method for enhancing dynamic vascular patterns of focal liver lesions in contrast ultrasound. IEEE Ultrason Symp 2007; Oct:546-549
14. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med 1991; 324:1-8
15. Marcus CD, Ladam-Marcus V, Cucu C, Bouché O, Lucas L, Hoeffel C. Imaging techniques to evaluate the response to treatment in oncology: current standards and perspectives. Crit Rev Oncol Hematol 2009; 72:217-238
16. Padhani AR, Neeman M. Challenges for imaging angiogenesis. Br J Radiol 2001; 74:886-890
17. Berriolo-Riedinger A, Touzery C, Riedinger JM, et al. [18F] FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 2007; 34:1915-1924 (Pubitemid 350212117)
18. Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH. Imaging angiogenesis: applications and potential for drug development. J Natl Cancer Inst 2005; 97:172-187
19. Greco P, Cormio G, Vimercati A, et al. Transvaginal color Doppler ultrasound for monitoring the response to neoadjuvant chemotherapy in advanced cervical cancer. Acta Obstet Gynecol Scand 1997; 76:169-172 (Pubitemid 27084722)
20. Bramer JA, Gubler FM, Maas M, et al. Colour Doppler ultrasound predicts chemotherapy response, but not survival in paediatric osteosarcoma. Pediatr Radiol 2004; 34:614-619
21. Singh G, Kumar P, Parshad R, Seith A, Thulkar S, Hosten N. Role of color Doppler indices in predicting disease-free survival of breast cancer patients during neoadjuvant chemotherapy. Eur J Radiol 2010 75:e158-e162 [Epub 2010 Jan 13]
22. Imuta N, Kinoshita N, Etani H, Yagita Y, Nukada T. The reproducibility of color Doppler duplex sonography in the measurement of renal arterial blood velocity. Ultrasound Med Biol 1997; 23:813-819 (Pubitemid 27349528)
23. Rettenbacher T. Focal liver lesions: role of contrast-enhanced ultrasound. Eur J Radiol 2007; 64:173-182
24. Bertolotto M, Pozzato G, Croce LS, et al. Blood flow changes in hepatocellular carcinoma after thalidomide administration assessed by reperfusion kinetics during microbubble infusion: preliminary result. Invest Radiol 2006; 41:15-21
25. Barabas K, Milner R, Lurie D, Adin C. Cisplatin: a review of toxicities and therapeutic applications. Vet Comp Oncol 2008; 6:1-18
26. Emmenegger U, Man S, Shaked Y, et al. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res 2004; 64:3994-4000 (Pubitemid 38697315)